Outside of the realm of immune system directed therapies, other BiTE have been developed targeting surface proteins, such as amivantamab that has been approved for patients with non-small cell lung cancer harboring an epidermal growth factor receptor (EGFR) exon 20 insertion mutation (67). This evidence concerns the gene EGFR and non-small cell lung carcinoma.